Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Status:
Terminated
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that
will enroll 1028 patients with at least moderately severe COPD over a three year period and
follow them at regular intervals for one year. The primary endpoint is time to first acute
exacerbation. Secondary endpoints include rates and severity of COPD exacerbations,
cardiovascular events, all-cause mortality, lung function, dyspnea, quality of life and
metoprolol-related side effects.
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
United States Department of Defense University of Alabama at Birmingham